# FiNC Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/finc-technologies

- Industry: Healthcare IT
- Headquarters: Tokyo, Japan
- Total disclosed funding: $81M
- Latest round: Series G (May 16, 2022)
- Investors on record: 25

## About

Founded in 2012 and based in Tokyo, Japan, FiNC Technologies Inc. offers software solutions that offer health and wellness monitoring, advice, nutrition monitoring, and related services. In March 2024, the firm raised an amount in venture funding from investor Rohto Pharmaceutical. As of 2024, the company is headed by its CEO Yasuo Koizumi. 

FiNC's offering is the FiNC app, which uses advanced AI to offer personalized beauty and health guidance. The app tracks metrics such as weight, steps, sleep, and diet, providing users with tailored advice and recommendations. Additionally, FiNC Mall, the company's wellness select shop, allows users to purchase health and beauty products, including supplements and fitness equipment.

FiNC generates revenue through various channels, including subscription fees for advanced app features (FiNC Plus), sales of products on FiNC Mall, and its proprietary supplements. It offers carbohydrate management and advice report functions, for a monthly fee of 480 YEN.

The company plans to utilize the March 2024 funding to implement corporate health management and socially implement digital services tailored to its customers.

## Funding rounds

- Series G, May 16, 2022, $3M — Japan Post Capital
- Series D, Sep 25, 2018, $50M — NEC, Chubu Electric Power, Ezaki Glico, Canopius AG, SBI Investment, Yokohama Capital, Dai-ichi Life Asset Management Co. Ltd, Kodansha, Rohto Pharmaceutical, Hiroshima Venture Capital, Mizuho Securities Principal Investment, Takenaka Partners, J-Wave, Shiseido Venture Partners, ArTra Corporation
- Series C, Aug 31, 2017, $9.7M — NEC, Mitsubishi UFJ Capital, Mitsubishi Estate
- Series C, Jan 13, 2017, $18M — Meiji Yasuda Life Insurance, SPARX Group, Dai-ichi Life Asset Management Co. Ltd, KAGOME CO,. Ltd., Rohto Pharmaceutical
- Series A, Sep 12, 2014, $0.3M — ITOCHU Technology Ventures, STRIVE, Link and Motivation, MID Venture Capital

## Investors

- ITOCHU Technology Ventures (https://capitalatlas.ai/funds/itochu-technology-ventures) — Series A
- STRIVE (https://capitalatlas.ai/funds/strive) — Series A
- Link and Motivation — Series A
- MID Venture Capital — Series A
- Meiji Yasuda Life Insurance — Series C
- SPARX Group (https://capitalatlas.ai/funds/sparx-group) — Series C
- Dai-ichi Life Asset Management Co. Ltd — Series C, Series D
- KAGOME CO,. Ltd. — Series C
- Rohto Pharmaceutical — Series C, Series D
- NEC — Series C, Series D
- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Series C
- Mitsubishi Estate — Series C
- Chubu Electric Power — Series D
- Ezaki Glico — Series D
- Canopius AG — Series D
- SBI Investment (https://capitalatlas.ai/funds/sbi-investment) — Series D
- Yokohama Capital (https://capitalatlas.ai/funds/yokohama-capital) — Series D
- Kodansha — Series D
- Hiroshima Venture Capital (https://capitalatlas.ai/funds/hiroshima-venture-capital) — Series D
- Mizuho Securities Principal Investment (https://capitalatlas.ai/funds/mizuho-securities-principal-investment) — Series D
- Takenaka Partners — Series D
- J-Wave — Series D
- Shiseido Venture Partners (https://capitalatlas.ai/funds/shiseido-venture-partners) — Series D
- ArTra Corporation — Series D
- Japan Post Capital (https://capitalatlas.ai/funds/japan-post-capital) — Series G